Divided FTC conditionally clears Danaher/GE biopharma merger

Danaher must divest products in several markets to allay concerns that its $21 billion acquisition of GE’s biopharma business would harm competition, the Federal Trade Commission has held.

Get unlimited access to all Global Competition Review content